Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

iCMLf Conversation: CML Highlights of ASH 2025 - Clinical overview

 

Photo Ehab Atallah 2

Expert:

Professor Ehab Atallah
Professor of Medicine and Section Head of Hematologic Malignancies,
Medical College of Wisconsin (USA)

Program:
Overview of significant clinical aspects presented during the conference, including:

1. New tyrosine kinase inhibitors to improve outcome

  • Allosteric myristoyl pocket inhibitors
    • CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML (03:47)
    • Efficacy of TGRX-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study (06:15)
  • ATP pocket binding inhibitors (3rd generation)
    • Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy in patients with TKI-resistant CP-CML in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations (07:59)

2. Combination therapy 

  • Improved long-term tolerability and efficacy of asciminib-based combination therapies in newly diagnosed CML patients - the FASCINATION trial (09:21)
  • ALERT CML: Asciminib as Initial Therapy with Addition of Lower Dose TKI's for Patients with CML who do not achieve DMR (11:40)

3. Dose increase for better outcome

  • Asciminib in CP-CML: Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients with 1 prior TKI (12:34)

4. Real-world evidence in advanced phase:

  • Management and outcomes of patients diagnosed with CML in blast phase: A multicenter analysis by the J Jean Khoury Cure CML Consortium (14:47)

5. ASH 2025 CML Blitz (16:34)


Click here for the biological highlights and the Q&A Session. 

If you have any questions or comments to the speaker, please email info@cml-foundation.org.